Skye Bioscience
SKYE on Nasdaq. Market value $39m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
We don't have fund holdings for this stock yet.
Big holders and activists
3 investors own more than 5%.
- Andrew J. Schwabat least 26.1%−4.1 pts(filed with 8 related holders)Since 22 September 2026
- TANG CAPITAL MANAGEMENT, LLCPassive investorat least 6.0%(filed with 5 related holders)Since 7 October 2026
- Sphera Funds Management Ltd.Passive investorat least 4.8%(filed with 2 related holders)Since 31 March 2025
- Schonfeld Strategic Advisors LLCPassive investorSold down below 5%Since 30 June 2025
| Holder | Stake | Since | |
|---|---|---|---|
Andrew J. Schwab | at least 26.1%−4.1 pts (filed with 8 related holders) | 22 September 2026 | |
TANG CAPITAL MANAGEMENT, LLC Passive investor | at least 6.0% (filed with 5 related holders) | 7 October 2026 | |
Sphera Funds Management Ltd. Passive investor | at least 4.8% (filed with 2 related holders) | 31 March 2025 | |
Schonfeld Strategic Advisors LLC Passive investor | Sold down below 5% | 30 June 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 1 sold $444,602.
- Schwab Andrew J.DirectorSold
- Date
- 23 September 2026
- Shares
- 119,379
- Price
- $1.61
- Value
- $192,200
- Schwab Andrew J.DirectorSold
- Date
- 22 September 2026
- Shares
- 28,700
- Price
- $1.65
- Value
- $47,355
- Schwab Andrew J.DirectorSold
- Date
- 16 September 2026
- Shares
- 33,892
- Price
- $1.91
- Value
- $64,734
- Schwab Andrew J.DirectorSold
- Date
- 20 August 2026
- Shares
- 7,700
- Price
- $0.32
- Value
- $2,464
- Schwab Andrew J.DirectorSold
- Date
- 19 August 2026
- Shares
- 68,140
- Price
- $0.35
- Value
- $23,849
- Schwab Andrew J.DirectorSold
- Date
- 18 August 2026
- Shares
- 300,000
- Price
- $0.38
- Value
- $114,000
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 23 September 2026 | Schwab Andrew J. Director | Sold | 119,379 | $1.61 | $192,200 |
| 22 September 2026 | Schwab Andrew J. Director | Sold | 28,700 | $1.65 | $47,355 |
| 16 September 2026 | Schwab Andrew J. Director | Sold | 33,892 | $1.91 | $64,734 |
| 20 August 2026 | Schwab Andrew J. Director | Sold | 7,700 | $0.32 | $2,464 |
| 19 August 2026 | Schwab Andrew J. Director | Sold | 68,140 | $0.35 | $23,849 |
| 18 August 2026 | Schwab Andrew J. Director | Sold | 300,000 | $0.38 | $114,000 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
2 serious warning signs in Skye Bioscience’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 10 Mar 2026, plus the 10-Q filed 13 Nov 2026 and 10 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern.”
Show the full paragraph
The Company’s continued existence is dependent on its ability to close its proposed Transaction or to raise sufficient additional funding to cover operating expenses. As of the date that these financials are filed, management estimates that the Company has sufficient capital through the Closing. However, the Company's continued operations beyond the fourth quarter of 2026 will depend on its ability to complete the proposed Transaction or to successfully raise additional capital through various potential sources, such as equity and/or debt financings, or strategic relationships. If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued.
From the 10-Q filed 13 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
Weak checks on its own accounts
SeriousThe company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.
“Specifically, the Company did not maintain effective review controls to verify the completeness and accuracy of award data and related compensation expense calculations provided by its third-party stock administration service provider, including changes associated with employee terminations and award expirations.”
Show the full paragraph
Management, under the supervision and with the participation of the Company’s Chief Executive Officer, who also serves as its principal financial and accounting officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of September 30, 2026. During the preparation and review of the financial statements included in this Quarterly Report, management identified a material weakness in the Company’s controls over stock-based compensation expense. Specifically, the Company did not maintain effective review controls to verify the completeness and accuracy of award data and related compensation expense calculations provided by its third-party stock administration service provider, including changes associated with employee terminations and award expirations. These deficiencies resulted in errors in reported award fair values and compensation expense. Based on this evaluation, management concluded that the Company’s disclosure controls and procedures were not effective at a reasonable assurance level as of September 30, 2026. Our remediation efforts with respect to this material weakness are continuing, and we have determined that this material weakness is continuing as of September 30, 2026.
From the 10-Q filed 13 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.